Abstract:e15607 Background: Colorectal cancer is one of the most common malignancies worldwide. Approximately 85% of colorectal cancers are thought to result from adenoma. However, the molecular mechanism of adenoma transformation into colorectal cancer is still unclear. Methods: Ninety-nine adenoma patients aged from 25 to 78 years old were enrolled in this study. We collected tissue sample from each patient and 77 matched blood samples. Pathological subtypes included tubular villous adenomas, villous adenomas, tubular adenomas, high-grade intraepithelial neoplasia, and polyps. Eighty-one stage I colorectal cancer patients (CRC I) were also enrolled in this study. All samples underwent Next-generation sequencing with a panel of 405 cancer related genes. Results: Mutational profiles of adenoma and CRC I patients were compared. The top 5 most frequently mutated genes in adenoma were APC (71%), KRAS (41%), ATM (33%), RIF1 (31%), SYNE1 (28%). While in CRC I patients, top 5 mutated genes were APC (78%), TP53 (57%), TTN (35%), KRAS (33%) and TCF7L2 (22%). There were significant differences between TP53 and TTN by chi-square test. The frequency, number and TMB of mutations in stage I colorectal cancer patients were significantly higher than those in various adenoma subtypes. Stage I colorectal cancer patients have more mutated genes enriched in the Wnt and Notch pathways than adenoma patients. We analyzed mutation signatures in CRC I and adenoma patients, and CRC I were more focused on mutation signatures of mismatch repair such as signature 1, signature 6, signature 10, and signature 15. A total of 391 mutations were identified in tissue samples, while 130 mutations were found in plasma cell-free DNA, with 116 mutations shared between them. The two genes with the highest consistency between tissue and blood were PAX7 and KMT2D. Conclusions: TP53 and TTN are associated with the transition from CRC I to adenoma, and Wnt and Notch pathways may also be involved. PAX7 and KMT2D mutations frequently found in adenoma tissue and blood cfDNA demonstrate the diagnostic potential of these two genes in clinic.

The progress of hepatocellular adenoma malignant transforming in molecule mechanism researches

[Role of Wnt/β-catenin Signaling Pathway in Promoting Tumorigenesis of Hepatocellular Carcinoma].

Research Progress of MicoRNA in Molecular Targeting Treatment of Hepatocellular Carcinoma

[Advances in the Role of Exosome-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma].

Whole‐exome sequencing‐based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma

Progress on Malignant Transformation of Hepatic Stem Cells

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Advances in the Study of Mechanisms of Malignant Transformation of Salivary Pleomorphic Adenoma

Biological Characteristics of Pancreatic Ductal Adenocarcinoma: Initiation to Malignancy, Intracellular to Extracellular.

A Shifting Paradigm in Diagnosis and Management of Hepatic Adenoma

Advances on Molecular Mechanism of Hepatitis B Virus-Induced Hepatocellular Carcinoma.

Research progression of molecular biology in cholangiocarcinoma

Bicluster and Pathway Enrichment Analysis Related to Tumor Progression of Hepatocellular Carcinoma

Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview

Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma

The advanced development of molecular targeted therapy for hepatocellular carcinoma

A study on the genomic alterations of transformation from colorectal adenoma to colorectal cancer.

Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line.

The mechanistic, diagnostic and therapeutic novel nucleic acids for hepatocellular carcinoma emerging in past score years

The Genetic Changes of Hepatoblastoma

Molecular markers for the monitoring of malignant transformation of hepatocytes and early diagnosis of liver cancer